Zoetis stock is trading -14.56% below its average target price of $216.87 after marking a 6.0% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $187.0 to $248.0 per share.
The stock has a very low short interest at 1.2%, and a short ratio of 2.22. The company's insiders own 0.2% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.3% of Zoetis's shares being owned by this investor type.
Institutions Invested in Zoetis
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 9% | 40,749,571 | $7,550,487,737 |
| 2024-03-31 | Blackrock Inc. | 8% | 36,731,396 | $6,805,960,118 |
| 2024-03-31 | State Street Corporation | 4% | 19,570,006 | $3,626,126,280 |
| 2024-03-31 | State Farm Mutual Automobile Insurance Co | 4% | 16,151,379 | $2,992,688,906 |
| 2024-03-31 | Bank of America Corporation | 3% | 13,963,226 | $2,587,246,051 |
| 2024-03-31 | Morgan Stanley | 3% | 12,883,471 | $2,387,178,255 |
| 2024-03-31 | Alliancebernstein L.P. | 3% | 12,410,543 | $2,299,549,429 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 10,048,001 | $1,861,794,037 |
| 2024-03-31 | Price (T.Rowe) Associates Inc | 2% | 9,372,104 | $1,736,557,087 |
| 2024-03-31 | Wellington Management Group, LLP | 2% | 9,254,609 | $1,714,786,439 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Zoetis.
